Rosuvastatin News and Research

RSS
Health Canada approves Mylan-Rosuvastatin Calcium Tablets

Health Canada approves Mylan-Rosuvastatin Calcium Tablets

China Pharma revenue increases 9% to $81.2M for full year 2011

China Pharma revenue increases 9% to $81.2M for full year 2011

Kowa announces data of LIVALO vs. Crestor on pharmacodynamics of warfarin

Kowa announces data of LIVALO vs. Crestor on pharmacodynamics of warfarin

Enrollment complete in SUSTAIN Phase 2b clinical trial for atherosclerotic CVD

Enrollment complete in SUSTAIN Phase 2b clinical trial for atherosclerotic CVD

Cholesterol drugs clash head on

Cholesterol drugs clash head on

Rosuvastatin as effective as atorvastatin in reversing atherosclerosis

Rosuvastatin as effective as atorvastatin in reversing atherosclerosis

China Pharma third quarter revenue increases 12% to $21.0 million

China Pharma third quarter revenue increases 12% to $21.0 million

High levels of calcium in coronary arteries increase risk of stroke, heart attack

High levels of calcium in coronary arteries increase risk of stroke, heart attack

China Pharma second quarter revenue increases 18% to $19.6 million

China Pharma second quarter revenue increases 18% to $19.6 million

China Pharma first quarter revenue increases 20% to $18.1 million

China Pharma first quarter revenue increases 20% to $18.1 million

AstraZeneca introduces new CRESTOR and NEXIUM customer service websites

AstraZeneca introduces new CRESTOR and NEXIUM customer service websites

Top-line results from Amarin's AMR101 Phase 3 trial in patients with high triglycerides

Top-line results from Amarin's AMR101 Phase 3 trial in patients with high triglycerides

Clinical trial to determine whether Crestor can prevent new colon tumors after surgery

Clinical trial to determine whether Crestor can prevent new colon tumors after surgery

Jefferson begins patient recruitment for new clinical trail to prevent colon cancer

Jefferson begins patient recruitment for new clinical trail to prevent colon cancer

Abbott, AstraZeneca discontinue CERTRIAD development collaboration

Abbott, AstraZeneca discontinue CERTRIAD development collaboration

VYTORIN reduces major vascular events in patients with chronic kidney disease

VYTORIN reduces major vascular events in patients with chronic kidney disease

Surveyed cardiologists, PCPs perceive Crestor comparable to Lipitor in ability to reduce mortality

Surveyed cardiologists, PCPs perceive Crestor comparable to Lipitor in ability to reduce mortality

Cholesterol-lowering statin therapy benefits patients with calcium buildup in arteries

Cholesterol-lowering statin therapy benefits patients with calcium buildup in arteries

Top 10 Medical Innovations for 2011

Top 10 Medical Innovations for 2011